NetworkNewsBreaks – Trxade Group Inc. (NASDAQ: M
Post# of 174
Trxade Group (NASDAQ: MEDS) was featured in a recent equity research report published by Dougherty & Company LLC. The report reads, “We are initiating coverage of Trxade with a Buy rating and Price Target of $12. MEDS’ primary offering is a web-based platform connecting large suppliers of branded and generic drugs with retail and independent pharmacies. The platform offers full price transparency, comparing the prices and availability across a variety of suppliers. Its latest offering is a direct-to-consumer application equipped with telemedicine visits which includes home delivery of medications. MEDS nearly doubled revenue in 2019 and we model the company increasing sales at close to a 40% clip in 2020, while profitable for several quarters. We view the stock as a compelling, under-the-radar idea for small-cap growth investors seeking exposure to digital health and telemedicine. Our $12 Price Target is based on a 6x multiple on our 2021 forecast, a slightly lower multiple than comps which we justify with a small cap discount, but considering also MEDS’ superior growth rate.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer